EP3796912
ANDFJÖLGUNAR-EFNASAMBÖND OG TVÍSÉRTÆKT MÓTEFNI GEGN BCMA OG CD3 TIL SAMSETTRAR NOTKUNAR
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
22.5.2019EP published:
15.2.2023EP application number:
19732494.0
EP translation filed:
10.5.2023Grant published:
15.6.2023EPO information:
European Patent Register
Max expiry date:
21.5.2039Expiry date:
21.5.2026Next due date:
31.5.2026
Title in English:
ANTIPROLIFERATIVE COMPOUNDS AND BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 FOR COMBINED USELanguage of the patent:
English
Timeline
Today
22.5.2019EP application
15.2.2023EP Publication
10.5.2023Translation submitted
15.6.2023Registration published
21.5.2026Expires
Owner
Name:
Celgene CorporationAddress:
86 Morris Avenue, Summit, NJ 07901, US
Inventor
Name:
PIERCE, Daniel, W.Address:
San Francisco, CA 94158, US
Name:
WONG, Lilly, L.Address:
San Diego, CA 92121, US
Agent
Name:
G.H. Sigurgeirsson ehf.Address:
Borgartúni 26, 105, Reykjavík,
Priority
Number:
201862675639 PDate:
23.5.2018Country:
US
Classification
Categories:
A61K 31/497, A61K 39/00, A61P 35/00, A61K 31/496, A61K 39/395, A61K 45/06, A61P 35/02, C07K 16/28
Annual fees
Number
Paid
Expires
Payer
Number: 5
Paid: 12.4.2023
Expires: 21.5.2024
Payer: Árnason Faktor ehf.
Number: 6
Paid: 9.4.2024
Expires: 21.5.2025
Payer: Árnason Faktor ehf.
Number: 7
Paid: 9.5.2025
Expires: 21.5.2026
Payer: Árnason Faktor ehf.